首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 218 毫秒
1.
人乳头瘤病毒与P 53协同致膀胱移行细胞癌关系的研究   总被引:7,自引:0,他引:7  
目的 研究人类乳头瘤病毒(HPV)6、11、16和18型及P53与膀胱移行细胞癌的关系。方法 采用聚合酶链反应(PCR)方法检测了75例膀胱移行细胞癌组织中HPV的感染,免疫组化SP法检测P53蛋白表达情况。结果 膀胱移行细胞癌组织中HPV6、11、16和18的阳性率分别为6.7%(5/75),5.3%(4/75),33.3%(25/75)和6.7%(5/75)。低危型HPV(6或11)阳性率为9.3%(7/75),高危型HPV(16或18)阳性率为34.7%(26/75)。同一膀胱癌组织中两种以上(包括两种)HPV亚型感染8例,占10.6%。HPV6、16和18型之间感染阳性率在肿瘤有无转移组中差异显著(P〈0.05),HPV16、18的阳性率在肿瘤病理分级中差异有极显著性(P〈0.01)。HPV DNA型别  相似文献   

2.
尖锐湿疣组织中人乳头状瘤病毒的检测   总被引:5,自引:0,他引:5  
用免疫组织化学、DNA原位杂交和聚合酶链反应技术,检测人生殖器尖锐湿疣和女阴假性湿疣组织中人乳头状瘤病毒衣壳抗原(HPV-Ag)和病毒核酸序列(HPV-DNA),并观察了HPV在尖锐湿疣组织中的分布特点与病变组织学改变的关系。结果显示尖锐湿疣中HPV-Ag阳性率为71.4%(35/49);原位杂交HPV6/11DNA阳性率为96.5%(28/29);PCR扩增后尖锐湿疣HPV6/11/16/18DNA阳性率为100%(53/53);假性湿疣HPV6/11/16/18DNA阳性率为21.4%(3/14)。观察HPV-Ag和HPV-DNA分布,表明HPV增殖性感染和尖锐湿疣特异的病理改变密切相关。  相似文献   

3.
目的:探讨人乳头瘤病毒(HPV)与食管鳞状细胞癌的关系。方法:采用多重引物多聚酶链反应(PCR)的免疫组化技术、对104例食管鳞癌进行HPV DNA和病毒癌基因E6蛋白检测。结果:HPV DNA阳性者占50.96%(53/104),其中HPV16型DNA49.06%(26/53),HPV18型 DNA5.6%(3/53),HPV6/11 DNA7.5%(4/53);两上或三个类型的混合感染占37.  相似文献   

4.
HPV16,18E6蛋白与p21ras,p53在食管癌组织中表达   总被引:3,自引:0,他引:3  
采用SP免疫组化法对52例食管鳞状细胞癌和30例食管粘膜慢性炎(对照组)进行高危HPV16、18E_6和p21ras、p53癌基因产物的检测。结果表示:鳞癌组中E_6的阳性率为67.31%,与对照组相比差异有极显著性(P<0.001),其中E_6与p53呈双阳性者为55.77%(29/52)、89.66%(26/29),显示两者阳性着色出现在部分相同区域同一癌细胞核内(似表明E_6可与p53结合形成复合物从而导致野生型p53的降解)。本组p21ras与p53、p53与E_6的阳性表达均具相关性(P<0.05)。提出HPV16、18感染与本地区食管癌病因学密切相关,E_6抗体是诊断HPV16、18感染的良好标记。  相似文献   

5.
用聚合酶链反应检测食管癌组织中人乳头瘤病毒DNA   总被引:9,自引:1,他引:9  
应用聚合酶链反应(PCR)技术对汕头市区68例食管癌的石蜡包埋标本进行人乳头瘤病毒(HPV)DNA序列检测,结果显示,HPVDNA总阳性率为66.18%(45/68),检出型别主要为HPV6、11、16,检出率分别为27.94%、36.76%和27.94%,经统计学处理三型间无显著性差异;HPV-18及未定型别各占8.82%。值得注意的是HPV感染中多重感染占阳性病例的53.33%(24/45)。初步结果表明,汕头市食管癌高发区有较高的HPV感染率,此与食管癌的发生,可能有密切关系。  相似文献   

6.
人喉癌组织中人乳头瘤病毒DNA的检测   总被引:6,自引:0,他引:6  
目的为探讨喉癌与人乳头瘤病毒(HPV)感染的关系和HPV在喉癌中基因组型的分布与表达。方法应用聚合酶链反应技术(PCR)制备非放射性探针标记物-地高辛标记HPV共有引物探针,对146例喉不同病变的新鲜组织标本(喉癌68例,喉其它病变48例,正常喉组织30例),进行HPV6,11,16,18,31,33,35,42,58共9型HPVDNA感染的检测;阳性者用多重引物PCR方法分型。结果喉癌HPV感染阳性率45.6%(31/68),喉癌颈转移淋巴结组织阳性率20.0%(3/15),喉癌前病变阳性率11.8%(2/17),声带息肉阳性率6.3%(1/16),15例癌旁及15例癌周正常喉组织均为HPVDNA阴性。HPVDNA型别分布在喉癌中以HPV16、18型为主,喉良性病变中以HPV6、11型为主。结论喉癌发生与HPV感染有关。  相似文献   

7.
人乳头状瘤病毒不同型别与宫颈病变的相关性研究   总被引:8,自引:1,他引:8  
目的探讨人乳头状瘤病毒(HPV)不同型别与宫颈病变性质的关系。方法应用PCR技术和原位杂交方法对61例宫颈上皮内瘤(CervicalintraepithelialNeoplasiaCIN)和12例宫颈鳞癌(SCC)进行HPV6B/11、16、18DNA检测。结果PCR检测结果显示HPV6、11主要分布于低度鳞状上皮内病变(619%)和一部分CINⅡ中(20%),而在CINⅢ和SCC中检测不到;HPV16、18的检出率随CIN级别增高而增加,在SCC中高达833%。原位杂交结果显示在低度鳞状上皮内病变中,地高辛(Dig)标记的HPV6B/11、16、18DNA杂交物质在核中均呈细颗粒状,为“游离型”。上述杂交阳性信号形态亦出现于CINⅡ的所有HPV6B/11及部分HPV16、18型感染中,而CINⅢ和宫颈鳞癌及部分CINⅡ中,其杂交阳性信号均为非颗粒状的“整合型”。结论低度鳞状上皮内病变是以HPV6、11低危型为主的多型别病毒的繁殖性感染,CINⅢ和宫颈鳞癌为HPV16、18高危型病毒的整合型感染,而在CINⅡ中存在着HPV6,11和HPV16,18的繁殖性感染及HPV16,18的整合型感染  相似文献   

8.
慢性宫颈炎患者宫颈中人乳头瘤病毒基因的检测   总被引:6,自引:0,他引:6  
应用聚合酶链反应技术检测正常妇女与慢性宫颈炎患者宫颈人乳头瘤病毒感染情况的结果显示,南京市慢性宫颈炎患者HPV-DNA总阳性率达58.6%;HPV6,11,16,18型阳性率分别为29.3%,30.7%,28.6%和34.3%,而正常妇女中HPV总阳性率为19.4%,4个型别HPV阳性率为9.7%,16.1%,3.2%和3.2%,明显低于宫颈炎患者。如皋市慢性宫颈炎患者HPV-DNA总阳性率高达8  相似文献   

9.
应用人乳头瘤病毒(HPV)通用引物介导的聚合酶链反应(PCR)技术检测了15例结肠癌石蜡包埋病理组织切片中HPVDNA,其中10例呈阳性扩增(阳性率为66.7%)。12例正常结肠组织经上述PCR检测均呈阴性反应。阳性扩增产物经核酸斑点杂交进行HPV型别分析,HPV16型占4例(40.0%),18型1例(10.0%),16/18型5例(50.0%),未检出其他HPV型别。表明HPV可能对结肠癌的发生具有病原相关性。  相似文献   

10.
妊娠期人乳头瘤病毒的感染状况及母婴传播的研究   总被引:6,自引:0,他引:6  
应用聚合酶链反应检测孕妇尖锐湿疣(CA)组织、无CA孕妇宫颈分泌物、外周血及羊水、新生儿咽分泌物、脐血中人乳头瘤病毒(HPV)感染及母婴传播。结果表明:CA组织中HPVDNA阳性率为90.32%,以HPV6/11型为主;无CA孕妇宫颈分泌物中HPVDNA阳性率为35.71%,以HPV16/18型为主;孕妇血中HPVDNA阳性率为57.69%;母婴间经产道垂直传播率为44.44%,血性经胎盘传播传播率为60%。说明HPV不仅存在于CA组织中,还存在于无CA孕妇生殖道及外周血中,母婴间传播途径除产道外,还有胎盘传播  相似文献   

11.
The aim of this study was to gain some insight into the relationship of human papillomavirus (HPV) infection to p53 expression and to some pathological parameters in precancerous lesions of the larynx. Formalin-fixed paraffin-embedded tissue sections containing human laryngeal precancerous lesions were screened for p53 protein by immunohistochemistry with the monoclonal antibody DO7 and for the presence of HPV infection by polymerase chain reaction with consensus primers directed against the E6 gene. The presence of p53 protein was detected in 31 of 57 specimens (54.4%) including 7 of 9 cases with mild dysplasia (78%), in 4 of 9 cases with moderate dysplasia (44%), and in 15 of 23 cases with severe dysplasia (65%). Of 16 samples with keratotic benign squamous metaplasia, 5 were also p53 positive (31%). Of 6 samples that were HPV positive, all were of type 16. Interestingly, 3 of the 6 HPV-positive samples were p53 negative. There was 1 HPV-positive case with strong p53 staining and 2 HPV-positive cases with minimal p53 staining. The 2 HPV-positive cases with minimal p53 staining had mild dysplasia. The HPV-positive case with strong p53 staining displayed severe dysplasia. Of 23 cases that were both HPV and p53 negative, 11 presented with keratosis and no dysplasia, 5 with moderate dysplasia, and 7 with severe dysplasia. Our data indicate that nuclear accumulation of p53 protein, presumably resulting from p53 gene mutation, may occur in HPV-infected epithelial tissues. On the other hand, there are many precancer lesions, some exhibiting moderate or severe dysplasia, that are both HPV negative and p53 unreactive, suggesting that alterations of genes other than the E6 oncogene and the p53 tumor suppressor gene play a role in early laryngeal carcinogenesis.  相似文献   

12.
Twenty-two tissue samples of primary adenocarcinoma (adenoCA) of the uterine cervix were evaluated for the presence of HPV 16/18 DNA using the polymerase chain reaction (PCR). PCR was used to specifically amplify the E6-E7 gene region of HPV 16/18 DNA. The amplification products were analyzed using gel electrophoresis and Southern dot blotting with 32p labeled type-specific oligonucleotide probes. HPV 18 DNA was identified in 13/22 (59%) and HPV 16 DNA was identified in 5/22 (23%) of the tumors. There were no tumors with mixed infections. In three patients, two different specimens were evaluated, and there was concordance of HPV typing. The presence of squamous carcinoma in situ, koilocytosis and younger patient age were associated with an increased incidence of HPV 16/18 DNA detection. HPV 16/18 DNA was not detected in six metastatic adenoCA to cervix (four endometrial, two ovarian). We conclude that HPV 16/18 DNA is present in a significant proportion of primary adenoCA of the cervix, and we have identified some clinicopathologic associations. The detection of HPV DNA may be useful in distinguishing primary from metastatic adenoCA of the cervix.  相似文献   

13.
AIM: To ascertain the extent of retinoblastoma protein (pRB) expression in comparison to p53 protein and human papilloma viruses (HPV) 16/18 status in cervical carcinomas. METHODS: Fifty cases of invasive cervical carcinoma were HPV typed for genotypes 16 and 18 using consensus primers by polymerase chain reaction (PCR). Immunohistochemistry for pRB and p53 was done on formalin fixed tissue using microwave antigen retrieval and commercially available antibodies. RESULTS: Forty five cases were squamous carcinomas, three were adenocarcinomas, and two were adenosquamous carcinomas. Thirty one cases were HPV 16 positive and one was HPV 18. Sixteen cases showed +4 pRB expression and a further 11 were +3 positive. Seven cases were negative. Only five cases (10%) showed +4 p53 immunostaining, while seven were negative and 15 were +1. Of the 16 pRB +4 positive cases, one was negative for p53 and a further seven were +1 positive. This inverse pattern of staining between pRB and p53 had a p value of < 0.001. No correlation was observed between HPV 16/18 status and p53 and/or pRB staining. CONCLUSIONS: pRB is expressed in the majority of cases of cervical cancer (86%), with more than 75% (+4) of the tumour cell population being positive in 16 cases (32%). There appears to be a general inverse pattern of staining between pRB (high) and p53 (low) in cervical cancer. The expression of both pRB and p53 proteins is independent of the HPV 16/18 status of the tumour.  相似文献   

14.
To analyze the coexistence of human papilloma virus (HPV) infection and K-ras gene activation in cervical neoplasia, we investigated 31 (seven pre-invasive and 24 invasive) cervical carcinomas for "low-risk" (types 6 and 11) and "high-risk" (types 16 and 18) HPVs and K-ras point mutations using PCR-based technology. "Low-risk" HPVs were not detected in the group investigated; however, 20 of 31 (64%) cases were HPV 16 positive, while HPV 18 was found in only three (9.7%) samples (HPV 6/11 v. HPV 16/18, p < 0.0001; HPV 16 v. HPV 18, p < 0.0001; Fisher's exact test). There was a K-ras codon 12 point mutation in two of 31 (6.4%) neoplasms, with none of the cases showing a K-ras codon 13 point mutation. Two moderately differentiated squamous carcinomas showed K-ras exon 2 gene alterations. Interestingly, none of the pre-invasive cervical carcinomas displayed K-ras gene point mutations. The mean patient age did not differ significantly in the number of HPV-positive and -negative cases. A coexistence of "high-risk" human papillomavirus DNA with K-ras gene alterations was observed in three of 31 (9.7%) neoplasms (one IIA and two IB moderately differentiated cervical carcinomas). Our results suggest that "high-risk" HPVs coexist with K-ras gene alterations in a subset of moderately differentiated carcinomas of the cervix uteri.  相似文献   

15.
P16基因是一种新发现的肿瘤抑癌基因,已有人类许多肿瘤中检测出P16基因突变。我们应用PCR-SSCP-EB染色技术,从石蜡包理上卵巢上皮性肿瘤组织切片中检测中6基因第二外显子结果显示P16基因突变率为53.57%,表明P16基因与卵巢上皮性肿瘤发生密切相关。  相似文献   

16.
子宫颈腺癌中HPV16/18感染对p16Ink4a、Rb蛋白表达的影响   总被引:2,自引:2,他引:0  
目的研究16、18型人乳头瘤病毒(HPV16/18)DNA与细胞周期相关蛋白p16Ink4a、Rb在子宫颈腺癌中的表达情况及HPV16/18感染对p16Ink4a、Rb蛋白表达的影响。方法采用组织微阵列技术结合原位杂交和免疫组化EliVision二步法标记检测HPV16/18DNA和p16Ink4a、Rb蛋白在86例子宫颈腺癌、15例子宫颈腺上皮异型增生及24例慢性子宫颈炎组织中的表达。结果子宫颈腺癌组和子宫颈腺上皮异型增生组HPV16/18DNA阳性表达率分别为65·1%和46·7%,均明显高于慢性子宫颈炎组8·3%(P<0·01);p16Ink4a蛋白在子宫颈腺癌组的阳性表达率为74·4%,显著高于慢性子宫颈炎组33·4%(P<0·01)。Rb蛋白在子宫颈腺癌组的阳性表达率为33·7%,低于慢性子宫颈炎组45·8%,但差异无显著性(P>0·05)。HPV16/18感染与子宫颈腺癌的病理分级和组织学类型无关,但与p16Ink4a蛋白表达呈正相关(P<0·05)。p16Ink4a与Rb蛋白表达与子宫颈腺癌的病理分级有关,G2、G3组p16Ink4a阳性表达率明显高于G1组(P<0·05),G3组Rb阳性表达率明显低于G1组(P<0·05)。p16Ink4a表达与子宫颈腺癌组织学类型有明显相关性,子宫内膜样腺癌p16Ink4a阳性表达率明显高于透明细胞腺癌(P<0·05)。结论子宫颈腺癌的发生与HPV16/18感染有关,HPV16/18感染可能影响p16Ink4a、Rb蛋白表达,使子宫颈腺上皮发生癌变并促进恶性发展。  相似文献   

17.
乳腺浸润性导管癌中HPV18、HPV16感染的研究   总被引:7,自引:0,他引:7  
目的 :了解乳腺浸润性导管癌中HPV18、HPV16的感染情况 ,分析其是否是乳腺癌发生的危险因素及与临床病理的相关性。方法 :根据HPV16、HPV18的DNA序列 ,合成相应特异的寡核苷酸片段 ,用加尾标记法制备地高辛标记探针 ,用原位杂交法检测 5 1例乳腺浸润性导管癌、10例相应正常乳腺上皮及 15例良性乳腺病变中HPV18、HPV16的感染 ,并分析其与患者发病年龄、肿块大小及淋巴结转移的相关性。结果 :浸润性导管癌中HPV18或 16的总阳性率达 70 6 % ,其中HPV18与HPV16的阳性率分别为 5 8 8%、4 5 1% ,均明显高于正常乳腺上皮的感染率 (30 0 %、10 0 % ;P <0 0 5 ) ;乳腺良性病变的HPV18、16阳性率分别是 6 0 0 %、6 0 % ,其中HPV18的阳性率亦显著高于正常乳腺上皮 (P <0 0 5 )。结论 :(1)HPV16和18可能是乳腺浸润性导管癌发生的致病因子 ,HPV18尚可能与乳腺良性病变的发生有关。 (2 )HPV的感染与患者年龄、肿块大小及淋巴结转移无相关性。  相似文献   

18.
We have examined a series of 37 oropharyngeal squamous cell carcinomas for the presence of HPV \611, 16, and 18 DNA by polymerase chain reaction (PCR)/Southern blotting and for p53 alterations by immunohistochemistry and mutation screening with temperature gradient gel electrophoresis (TGGE). HPV sequences were found in a total of 26 of 37 cancers (70.3%), most frequently HPV 16 (\2037) followed by HPV 18 (\1137). Double infections with HPV 16 and 18 were present in 5 tumours. p53 accumulation was detectable immunohistochemically in 21 of 37 carcinomas (56.8%). There were remarkable differences in the distribution of immunoreactive tumour cells in relation to the tumour grade. A mutation screening for p53 by TGGE, directed to the amplified exons 5–8, revealed p53 mutations in 14 of 37 carcinomas (37.8%). Mutations in two different exons were present in 3 tumours, 11 tumours being hit once. Exon 7 was mutated in 6 carcinomas, exons 5 and 8 in 4 cases, and exon 6 in 3 cases. When grouping the tumours with p53 mutation according to their HPV state, HPV-positive cases showed slightly more mutations (\1126) than HPV-negative cases (\311). Only 5 of 37 carcinomas (13.5%) contained neither HPV DNA nor p53 alterations. Our results indicate that high-risk HPV and p53 mutations frequently coexist in oropharyngeal carcinomas, in contrast to genital tumours, notably carcinomas of the cervix uteri. This may reflect different pathways in carcinogenesis in squamous cell epithelium from different sites.  相似文献   

19.
目的探讨HPV16感染及其E6/E7基因变异与宫颈病变的相关性。方法采用导流杂交技术进行HPV感染分型检测,PCR扩增出80份HPV16阳性宫颈病变的E6/E7基因、克隆入pMD18-T载体,双向测序分析基因变异与宫颈病变相关性。结果HPV16在宫颈病变患者中的检出率最高为33.3%(154/463),与病变程度相关(P<0.05)。E6/E7基因72份测序成功,DNA序列变异发生率为88.9%(64/72)。氨基酸序列E6-D32E(T96G)和E7-N29S(A86G)位点突变同时伴随存在,D32E/N29S的检出率为38.9%(28/72),与宫颈病变程度相关(P<0.05)。结论HPV16是北京地区来源的宫颈病变中最常见的致病型,其D32E/N29S变异与病变程度相关。  相似文献   

20.
Human papilloma virus (HPV) is regarded as a causative carcinogenic agent in anogenital squamous cell carcinoma (SCC), but there is controversy about its etiologic role in esophageal SCC (ESCC). In this study, we attempted to clarify whether HPV infection plays a crucial role in the development of ESCC by analysis of multiple factors. These included: detection of HPV DNA; evaluation of immunohistochemical assays for HPV-related cell cycle regulators and apoptosis by the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling method; and genetic analysis of the p53 gene. Twenty of the 48 ESCC examined (42%) were found to be positive for the HPV genome by polymerase chain reaction. They comprised 16 cases with the HPV16 subtype, three with the HPV18 subtype, and one with both HPV16 and 18. Immunohistochemical analysis revealed that the expression of p21/WAF-1 was significantly decreased in HPV-positive cases (chi2 = 9.2614; P = 0.0023). Furthermore, the 10 apoptosis-negative (< or =10%) cases of HPV-positive SCC were almost exclusively p21/WAF-1-negative (chi2 = 12.1406; P = 0.0005), indicating the significance of the relationship between HPV infection and the phenotype that is expected from HPV-induced inhibition of p53. Although 14 cases possessed missense and deletion mutations of the p53 gene (of which four mutations were found in HPV-positive ESCC), no accumulation of the mutation was defined in the phenotype, suggesting that distinct mutation processes might be involved in HPV-negative and -positive ESCC. The data provide significant support for the hypothesis that HPV infection may play a crucial role in the oncogenesis of some ESCC.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号